Medical News

RSS

Kleinert Kutz selects ChartLogic EHR Suite

The Kleinert Kutz Hand Care Center of Kentucky with 12 physicians and five offices has selected the ChartLogic EHR Suite. The orthopedic medical group and surgical center is one of the largest hand surgery programs in the world, handling more than 65,000 patient visits per year with offices in Lexington and Louisville, KY and New Albany, IN.

9 Nov 2011

Micell announces preliminary data from MiStent Sirolimus DES clinical study

Micell Technologies, Inc. today announced the release of preliminary data from the first-in-human clinical study of the MiStent Sirolimus Drug Eluting Coronary Stent System (MiStent DES), a thin-strut drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating designed for controlled drug release.

9 Nov 2011

AMRI reports $50.2 million total revenue for third quarter 2011

...

9 Nov 2011

Mesa Labs declares regular quarterly dividend of $.13 per share

Mesa Laboratories, Inc. today announced that its Board of Directors has declared a regular quarterly dividend of $.13 per share of common stock, up from $.12 per share last quarter.

9 Nov 2011

Heeding Gates's suggestions to fill global development finance hole without spending more money

In his Foreign Policy column, "The Optimist," Charles Kenny, a senior fellow at the Center for Global Development and a Schwartz fellow at the New America Foundation, responds to a speech to G20 leaders last week by Bill Gates, co-chair of the Bill & Melinda Gates Foundation, in which he "suggested that a financial transactions tax, alongside additional taxes on tobacco and carbon, could be used to help rich countries meet a global target of committing 0.7 percent of GDP to development aid."

9 Nov 2011

University of Houston to enhance cancer research facilities

Thanks to almost $1 million in new funding from the Cancer Prevention and Research Institute of Texas (CPRIT), the University of Houston (UH) will soon be enhancing its cancer research facilities.

9 Nov 2011

Encouraging interim results from daclatasvir Phase IIb study in genotype 1 and 4 HCV patients

Bristol-Myers Squibb Company today announced interim results from a Phase IIb clinical trial (COMMAND-1) of 395 treatment-naïve, genotype 1 and 4 hepatitis C infected patients in which two doses of the investigational NS5A replication complex inhibitor daclatasvir (BMS-790052), in combination with peginterferon alfa and ribavirin (alfa/RBV), achieved higher virologic response rates through Week 12 than the alfa/RBV control group, with comparable rates of adverse events.

9 Nov 2011

Positive results from ChemoCentryx CCX354 Phase II study on RA

ChemoCentryx, Inc., today announced that it reported positive Phase II results for CCX354 at the Annual Meeting of the American College of Rheumatology.

9 Nov 2011

AcelRx reports revenue of $408,000 for third quarter 2011

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, reported financial results today for the third quarter and nine months ended September 30, 2011.

9 Nov 2011

BioSpecifics reports $0.3M net income for third quarter 2011 vs. $0.5M net loss for third quarter 2010

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in Europe today announced its financial results for the third quarter ended September 30, 2011 and provided a corporate update. For the quarter, the Company reported net income of $0.3 million or $0.04 per share on a basic and on a fully diluted basis.

9 Nov 2011

Micromet's blinatumomab data to be reported at 53rd ASH annual meeting

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that data on its lead product candidate blinatumomab (MT103) will be reported at the 53rd Annual American Society of Hematology (ASH) Annual Meeting, to be held December 10 - 13 in San Diego, California.

9 Nov 2011

Boston Scientific reports positive long-term data from PERSEUS clinical program

Boston Scientific Corporation reports positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the ION (TAXUS Element) Paclitaxel-Eluting Platinum Chromium Stent System versus prior-generation paclitaxel-eluting stents.

9 Nov 2011

Political cartoon: 'Super Trapped?'

Kaiser Health News provides a fresh take on health policy developments with "Super Trapped?" by Steve Kelley.

9 Nov 2011

'Second hit' determines immune response against developing Burkitt's lymphoma

The human c-myc gene encodes a transcription factor (MYC) involved in the regulation of a vast number of other genes - it has been estimated that the transcription of about one in six genes is somehow under the control of MYC.

9 Nov 2011

Global Fund delays closing date for round 11 applications, says disbursements may not be available until 2013

The Global Fund to Fight HIV, TB and Malaria has delayed the closing date for applications for its next round of funding, reduced the estimated amount of money that will be available in that round, and potentially delayed the disbursement of the funds until 2013, PlusNews reports.

9 Nov 2011

Fluidigm third quarter total revenue increases 25% to $10.6 million

Fluidigm Corporation today announced its financial results for the third quarter ended September 30, 2011.

9 Nov 2011

Scripps scientist receives Novo Nordisk grant for research into diabetes

Andrew Butler, an associate professor in The Scripps Research Institute's Department of Metabolism and Aging, has been awarded one million dollars in funding over the next two years to further his research into a novel protein with the potential to improve the understanding and future treatment of diabetes.

9 Nov 2011

RNS system offers significant relief to patients with intractable seizures

Brain stimulation, already approved by the U.S. Food and Drug Administration for the treatment of Parkinson's disease and essential tremor, has now been shown to offer significant relief to patients with intractable seizures for whom drugs and other treatments have not worked.

9 Nov 2011

Inova Labs secures $17.5M in Series B round of equity financing

Inova Labs, a privately held medical device company focused on developing innovative products for the Chronic Obstructive Pulmonary Disease (COPD) market, announced today that it has secured a Series B round of equity financing for up to $17.5M from an investment syndicate led by Latterell Venture Partners, based in San Francisco, Calif.

9 Nov 2011

Clinton expected to urge U.S., other countries to intensify HIV/AIDS prevention efforts in speech on Tuesday

In a speech to be delivered at the NIH, "Secretary of State Hillary Clinton is expected to call Tuesday for a new push by the U.S. and other countries to harness recent science to stem the HIV/AIDS pandemic," the Wall Street Journal reports.

9 Nov 2011